Working… Menu

Barrett's Esophagus Patient Registry (BPR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01776346
Recruitment Status : Recruiting
First Posted : January 28, 2013
Last Update Posted : January 28, 2013
Information provided by (Responsible Party):
Chin Hur, Massachusetts General Hospital

Brief Summary:
The ultimate goal of the Barrett's Esophagus Patient Registry is to help develop more effective targeted screening strategies and treatment options for Barrett's esophagus and esophageal adenocarcinoma (EAC). We plan to do by developing a registry that will serve as a platform. Examples of analyses could include identifying genetic determinants and biomarkers that predict BE, progression of BE to EAC, as well as the response to therapies.

Condition or disease
Barrett Esophagus Esophageal Adenocarcinoma Gastroesophageal Reflux

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 750 participants
Observational Model: Case Control
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Barrett's Esophagus Patient Registry
Study Start Date : January 2011
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Barrett's Esophagus/Esophageal Adenocarcinoma
Patients who have Barrett's esophagus or esophageal adenocarcinoma.
Healthy control

Primary Outcome Measures :
  1. Progression to esophageal adenocarcinoma [ Time Frame: 5 years (on average although follow-up will continue) ]

Secondary Outcome Measures :
  1. Identify and validate genetic determinants that predict progression of BE to EAC and predict response to BE therapy [ Time Frame: 5 years on average ]
  2. Evaluate the natural history of BE with and without treatment based on clinical, functional and economic outcomes of the cases [ Time Frame: 5 years on average ]

Biospecimen Retention:   Samples With DNA
Serum (from whole blood), plasma (from whole blood), tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients who have been seen at Massachusetts General Hospital.

Inclusion Criteria:

  • Barrett's (BE): Patients who have Barrett's esophagus (all stages: Barrett's metaplasia, low-grade dysplasia, high-grade dysplasia) based upon standard endoscopic and histologic criteria.
  • Adenocarcinoma (EAC): Patients who have esophageal adenocarcinoma.
  • The control cohort will include patients ages 18 and older with no prior history of BE and EAC. These may include patients who are being seen or have been previously seen at MGH GI Associates for conditions including gastroesophageal reflux disease, peptic esophagitis, eosinophilic esophagitis, esophageal motility disorders such as achalasia and nutcracker esophagus.

Exclusion Criteria:

  • Inability or unwillingness to provide blood samples.
  • History of known bleeding disorders.
  • Currently awaiting organ transplantation.
  • Having an acute or severe chronic illness such as congestive heart failure or any other condition that would prohibit performing the endoscopy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01776346

Layout table for location contacts
Contact: Katherine Perzan, BA 617-726-1431

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Katherine Perzan, BA    617-726-1431   
Sponsors and Collaborators
Massachusetts General Hospital

Additional Information:

Layout table for additonal information
Responsible Party: Chin Hur, Principal Investigator; MD, MPH, Massachusetts General Hospital Identifier: NCT01776346     History of Changes
Other Study ID Numbers: 2010P002224
First Posted: January 28, 2013    Key Record Dates
Last Update Posted: January 28, 2013
Last Verified: January 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Barrett Esophagus
Gastroesophageal Reflux
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Precancerous Conditions